132 related articles for article (PubMed ID: 37119179)
1. Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis.
Zhang X; Yip TC; Tse YK; Hui VW; Li G; Lin H; Liang LY; Lai JC; Chan HL; Chan SL; Kong AP; Wong GL; Wong VW
Hepatology; 2023 Dec; 78(6):1816-1827. PubMed ID: 37119179
[TBL] [Abstract][Full Text] [Related]
2. Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease.
Zhang X; Wong GL; Yip TC; Cheung JTK; Tse YK; Hui VW; Lin H; Lai JC; Chan HL; Kong AP; Wong VW
Hepatology; 2022 Nov; 76(5):1409-1422. PubMed ID: 35334125
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.
Golabi P; Paik JM; Kumar A; Al Shabeeb R; Eberly KE; Cusi K; GunduRao N; Younossi ZM
Metabolism; 2023 Sep; 146():155642. PubMed ID: 37380016
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan.
Akuta N; Kawamura Y; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
BMC Gastroenterol; 2018 Nov; 18(1):165. PubMed ID: 30400829
[TBL] [Abstract][Full Text] [Related]
5. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus.
Mallet V; Parlati L; Martinino A; Scarano Pereira JP; Jimenez CN; Sakka M; Bouam S; Retbi A; Krasteva D; Meritet JF; Schwarzinger M; Thabut D; Rufat P; Bonnefont-Rousselot D; Sogni P; Pol S; Tsochatzis E;
J Hepatol; 2022 Feb; 76(2):265-274. PubMed ID: 34606913
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission.
Wild SH; Walker JJ; Morling JR; McAllister DA; Colhoun HM; Farran B; McGurnaghan S; McCrimmon R; Read SH; Sattar N; Byrne CD;
Diabetes Care; 2018 Feb; 41(2):341-347. PubMed ID: 29167212
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease.
Newton KP; Wilson LA; Crimmins NA; Fishbein MH; Molleston JP; Xanthakos SA; Behling C; Schwimmer JB;
Clin Gastroenterol Hepatol; 2023 May; 21(5):1261-1270. PubMed ID: 35709934
[TBL] [Abstract][Full Text] [Related]
8. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease.
Yilmaz Y; Senates E; Yesil A; Ergelen R; Colak Y
J Diabetes Complications; 2014; 28(3):328-31. PubMed ID: 24602757
[TBL] [Abstract][Full Text] [Related]
9. A Prediction Model Based on Noninvasive Indicators to Predict the 8-Year Incidence of Type 2 Diabetes in Patients with Nonalcoholic Fatty Liver Disease: A Population-Based Retrospective Cohort Study.
Cai X; Zhu Q; Cao Y; Liu S; Wang M; Wu T; Hong J; Ahmat A; Aierken X; Li N
Biomed Res Int; 2021; 2021():5527460. PubMed ID: 34095297
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
Kuchay MS; Choudhary NS; Mishra SK; Misra A
Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
[TBL] [Abstract][Full Text] [Related]
11. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.
Chen J; Song S; Li X; Bian D; Wu X
Saudi J Gastroenterol; 2022; 28(2):92-100. PubMed ID: 34810377
[TBL] [Abstract][Full Text] [Related]
12. SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong.
Lee CH; Mak LY; Tang EH; Lui DT; Mak JH; Li L; Wu T; Chan WL; Yuen MF; Lam KS; Wong CKH
Hepatology; 2023 Nov; 78(5):1569-1580. PubMed ID: 37055020
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes.
de Vries M; El-Morabit F; van Erpecum KJ; Westerink J; Bac ST; Kaasjager HAHK; de Valk HW
Eur J Intern Med; 2022 Jun; 100():77-82. PubMed ID: 35387749
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.
Cholankeril G; Kramer JR; Chu J; Yu X; Balakrishnan M; Li L; El-Serag HB; Kanwal F
J Hepatol; 2023 Mar; 78(3):493-500. PubMed ID: 36402450
[TBL] [Abstract][Full Text] [Related]
15. Trends in risk factor control and treatment among patients with non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory-wide study.
Zhang X; Yip TC; Tse YK; Hui VW; Li G; Lin H; Liang LY; Lai JC; Lai MS; Cheung JTK; Chan HL; Chan SL; Kong AP; Wong GL; Wong VW
Aliment Pharmacol Ther; 2023 May; 57(10):1103-1116. PubMed ID: 36815548
[TBL] [Abstract][Full Text] [Related]
16. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease.
Lee TY; Wu JC; Yu SH; Lin JT; Wu MS; Wu CY
Int J Cancer; 2017 Oct; 141(7):1307-1314. PubMed ID: 28509327
[TBL] [Abstract][Full Text] [Related]
17. Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes.
Rivera-Esteban J; Pons M; Planas A; Manzano-Nuñez R; Hernández C; Simó-Servat O; Bañeras J; Soler MJ; Seron D; Boixadera A; Augustin S; Simó R; Ferreira-González I; Genescà J; Pericàs JM;
Gastroenterol Hepatol; 2023 Nov; 46(9):682-691. PubMed ID: 36435379
[TBL] [Abstract][Full Text] [Related]
18. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.
Younossi ZM; Otgonsuren M; Henry L; Venkatesan C; Mishra A; Erario M; Hunt S
Hepatology; 2015 Dec; 62(6):1723-30. PubMed ID: 26274335
[TBL] [Abstract][Full Text] [Related]
19. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: Association and path analyses.
Li Z; Lin M; Liu C; Wang D; Shi X; Chen Z; Liu Y; Yang S; Li X
Cytokine; 2018 Aug; 108():145-150. PubMed ID: 29609136
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.
Bengtsson B; Stål P; Wahlin S; Björkström NK; Hagström H
Liver Int; 2019 Jun; 39(6):1098-1108. PubMed ID: 30829446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
